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SUMMARY 
Background: Over the last decades prolactin (PRL) has gained attention for its possible role in breast tumorigenesis. As all 
antipsychotics (although differences with respect to PRL elevation are large) have the propensity to induce hyperprolactinemia 
(HPRL), questions have arisen concerning the influence of PRL-elevating antipsychotic medications on breast cancer risk.  
Subjects and methods: A literature search (until January 2016), using the MEDLINE database, was conducted for English-
language published clinical studies to identify and synthesize data of the current state of knowledge concerning the relationship
between HPRL, breast cancer risk (factors) and antipsychotic medication.  
Results: Results of human prospective studies evaluating the relationship between pre-diagnostic circulating PRL levels and 
breast cancer risk are limited, equivocal and only correlational. Associations between higher circulating PRL levels and other breast 
cancer risk factors than nulliparity and hormone therapies mostly have been negative for both pre-and postmenopausal women. Until 
today, no causal link between (chronic) administration of antipsychotics and breast tumorigenesis in humans has been demonstrated.
Finally, several reports describe mechanisms of cancer protection with the PRL hormone as well as with antipsychotic medication.
Conclusion: The role of PRL in breast carcinogenesis therefore remains unclear, unconfirmed, yet controversial. Antipsychotics 
should not be withhold for breast cancer prevention reasons to patients in need of this sometimes life-saving medication, even if
classical breast cancer risk factors are present. 
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INTRODUCTION
Breast cancer is one of the most commonly diag-
nosed cancers (one in eight women will be diagnosed 
with breast cancer during their lifetime) and the leading 
cause of cancer death among females (Anothaisintawee 
et al. 2013, Ferlay et al. 2010, 2012, Matsen & Neu-
mayer 2013). Although breast cancer does occur in men 
as well, male breast cancer is rare (Desantis et al. 2014, 
Ruddy & Winer 2013).  
Breast cancer is not a single biological entity but a 
heterogeneous disease (Hachim et al. 2016, Litzenbur-
ger & Brown 2014). Several genetical and molecular 
subtypes of breast cancer with a distinctly different 
survival outcome and treatment response have been 
identified, including (but not limited to) luminal A, 
luminal B, human epidermal growth factor receptor 
(HER)2- overexpressing, and triple negative cancers 
(Barnard et al. 2015, Boyle 2012, Guiu et al. 2012, 
Hachim et al. 2016, Litzenburger & Brown 2014, 
Ringnér et al. 2013, Weigelt & Reis-Filho 2009).  
A range of risk factors for the development of breast 
cancer have been established (Barnard et al. 2015, 
Deroo et al. 2011, Gathani et al. 2014, Gaudet et al. 
2013, Jacobson et al. 2010, National Cancer Institute 
2016, Tworoger & Hankinson 2008, Venkitarama 
2014) (Table 1). Over the last decades prolactin (PRL) 
has gained attention for its possible role in breast 
tumorigenesis (da Silva et al. 2015, Froes Brandao et 
al. 2016, Tikk et al. 2014a). PRL is a neuroendocrine 
polypeptide hormone that is mainly synthesized in, and 
released into the blood circulation from lactotroph 
cells of the anterior lobe of the pituitary gland (i.e. the 
adenohypophysis) (Booth et al. 2015, Chen 2015, 
Peuskens et al. 2014). In addition to the adeno-
hypophysis several other extra-pituitary sites, inclu-
ding the mammary gland, physiologically secrete PRL 
(Ben-Jonathan et al. 2002, 2006, Muthuswamy 2012, 
Oakes et al. 2008, Peuskens et al. 2014), meaning that 
PRL reaches the breast both from the systemic circu-
lation as well as from local sources (Ben-Jonathan et 
al. 2002, LaPensee & Ben-Jonathan 2010). While the 
role of PRL in the normal development of the mam-
mary gland, breast enlargement during pregnancy and 
the induction and maintenance of milk production 
during lactation is well established, its role in breast 
cancer remains unclear and controversial (Hachim 
2016, Haddad & Wieck 2004, Peuskens et al. 2014). 
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Table 1. Breast cancer risk factors (Barnard et al. 2015, 
Deroo et al. 2011, Gathani et al. 2014, Gaudet et al. 2013, 
Jacobson et al. 2010, National Cancer Institute 2016, 
Tworoger & Hankinson 2008, Venkitarama 2014) 
Age (a woman’s risk of developing the disease increases 
as she gets older) 
Alcohol use 
Carrying breast cancer susceptibility genes (e.g., 
BRCA1 and BRCA2 mutations confer a 60% to 80% 
life-time risk for the development of breast cancer)  
Delayed childbearing (having a first full-term pregnancy 
after age 30) 
Diabetes mellitus 
Early menarche (beginning to menstruate before age 12) 
Hormone replacement therapy (HRT) (also called 
menopausal hormone therapy or MHT) 
Lack of breastfeeding 
Late menopause (starting menopause after age 55) 
Low physical activity 
Mammographic breast density (having dense breast) 
Nulliparity (never having been pregnant/children),  
Obesity 
Previous breast biopsy  
Personal or family history of breast or ovarian cancer  
Race (more often in White women, compared to South 
Asian and Black women)  
Radiation therapy to the breast 
Smoking (?) 
Like normal mammary gland development, breast 
carcinogenesis mostly is a hormonally dependent pro-
cess (Lee & Ormandy 2012). Therefore, female repro-
ductive hormones estrogen and progesterone, and 
possibly the PRL hormone, can have a major impact on 
breast cancer risk/growth and breast cancer cell move-
ment (Brisken & O’Malley 2010, da Silva et al. 2015, 
LaPensee & Ben-Jonathan 2010, Lee & Ormandy 2012, 
Perks et al. 2004). As the biological activities of PRL 
are mediated by specific membrane receptors (i.c. PRL 
receptor, PRLR) (Chen 2015), effects of this hormone 
on breast cancer have been proposed to be mediated by 
interaction with this receptor (Nitze et al. 2013), which 
is found in up to 80-90% of breast cancer cells 
(LaPensee & Ben-Jonathan 2010).  
The possible role of PRL in breast tumorigenesis 
has raised questions about the impact of antipsychotic-
induced hyperprolactinemia (HPRL) (usually defined 
as fasting levels >20 ng/ml in men, and >25 ng/ml in 
women) on breast cancer risk. Under normal physio-
logical conditions pituitary PRL synthesis and secre-
tion is tonically inhibited by the hypothalamus, 
mediated by a number of PRL inhibitory factors of 
which dopamine is the most important one (Muthus-
wamy 2012, Oakes et al. 2008, Peuskens et al. 2014). 
A blockade of dopamine D2 receptors (D2R) 
counteracts the tonic inhibitory effect of dopamine on 
the PRL secretion, resulting in disinhibition of PRL 
secretion. The stronger the dopamine D2R blockade, 
the higher the PRL elevation (Peuskens et al. 2014). 
Antipsychotics have a D2R-blocking effect and there-
fore elevate the secretion of PRL (Peuskens et al. 
2014). These medications are commonly divided into 2 
categories based on their mechanism of action and 
clinical profile. First generation antipsychotics (FGA), 
also known as typical antipsychotics, block dopamine 
receptors and, as a class, are associated with extra-
pyramidal side effects. Second generation antipsycho-
tics (SGA) antagonize both dopamine and serotonin 
receptors but affect dopamine to a lesser degree than 
FGA, resulting in fewer extrapyramidal side effects. 
However, these agents carry side effects (e.g., meta-
bolic) of their own (Stubbs et al. 2016, Vancampfort et 
al. 2015). Although all antipsychotics have the propen-
sity to induce HPRL, differences between antipsycho-
tic drugs with respect to PRL elevation are large 
(Peuskens et al. 2014). The highest rates of HPRL are 
consistently reported in association with the FGA and 
the SGA amisulpride, risperidone and paliperidone, 
while the SGA aripiprazole and quetiapine have the 
most favourable profile with respect to this outcome 
(Peuskens et al. 2014) (Table 2). Because of the wide-
spread (off-label) use of antipsychotic medication in 
the clinical field (antipsychotics not only remain the 
cornerstone of pharmacological treatment in patients 
with schizophrenia or other psychotic disorders, but 
are also frequently used for a wide range of other 
psychiatric or medical conditions), this topic certainly 
has a relevance for clinical practice. 
Table 2. Prolactin side-effect profile of second 
generation antipsychotics (Peuskens et al. 2014) 
 Prolactin elevation 
Amisulpride +++ 
Aripiprazole 0 
Asenapine + 
Clozapine + 
Iloperidone + 
Lurasidone ++ 
Olanzapine ++ 
Paliperidone +++ 
Quetiapine +/- 
Risperidone
Sertindole 
+++
+
Ziprasidone ++ 
0 = minimal to no risk;     +/- = minimal risk;     + = low risk; 
++ = moderate risk;     +++ = high risk 
Three important issues are discussed in this review: 
(1) is there evidence that elevated plasma PRL levels 
increase the risk of breast cancer? (2) does a 
relationship exist between elevated PRL levels and 
established breast cancer risk factors?, and (3) is there 
evidence that, particularly PRL-elevating, antipsychotic 
medication enhances breast cancer risk? 
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SUBJECTS AND METHODS 
A systematic search (until January 2016), using the 
MEDLINE database, was conducted for English-lan-
guage published clinical trials to synthesize the results 
concerning the current state of knowledge about breast 
cancer risk (factors) and its relationship to HPRL and 
antipsychotic medication. For the association between 
breast cancer risk and HPRL, we limited ourselves to 
prospective studies. Retrospective studies have little 
scientific value because they assess PRL levels after the 
woman had been diagnosed with breast cancer and 
introduce the potential for reverse causality bias. For the 
association between breast cancer risk and antipsychotic 
medication, case report studies were excluded. The 
following key words were used in various combina-
tions: ‘breast cancer’, ‘risk factor’, ‘prolactin’, ‘prolacti-
noma’, ‘prospective’, ‘antipsychotic’, ‘neuroleptic’, 
‘risperidone’, ‘olanzapine’, ‘quetiapine’, clozapine’, 
‘aripiprazole’, ‘amisulpride’, ‘sulpiride’, ‘paliperidone’, 
‘sertindole’, ‘ziprasidone’, ‘lurasidone’, ‘iloperidone’, 
‘asenapine’, ‘haloperidol’, ‘phenothiazines’, and 
‘butyrophenones’. We reviewed the reference lists of 
identified studies and reviews to detect any additional 
and potentially important articles.  
RESULTS 
Do elevated plasma PRL levels increase the risk 
of breast cancer? 
Data related to the association between pre-diag-
nostic circulating PRL levels and breast cancer risk are 
sparse. Until now, only two large database and five 
small prospective studies (Hankinson et al. 1999; 
Helzlsouer et al. 1994, Kabuto et al. 2000, Kwa et al. 
1981, Manjer et al. 2003, Tikk et al. 2014a, 2015, Two-
roger et al. 2004, 2006, 2007, 2013, 2015, Tworoger & 
Hankinson 2008, Wang et al. 1992) have addressed the 
associations between circulating PRL levels and breast 
cancer risk in the general population (Table 3). Those 
involving small sample sizes (maximum 173 breast 
cancer cases) (Helzlsouer et al. 1994, Kabuto et al. 
2000, Kwa et al. 1981, Manjer et al. 2003, Wang et al. 
1992) found no statistical significant relationship 
between PRL levels and breast cancer risk among either 
pre- or postmenopausal women. Although the larger 
database studies (The American Nurses’ Health Studies 
(NHS I/II) and the European Prospective Investigation 
into Cancer (EPIC) study) have shown that higher 
circulating PRL levels are associated with an increased 
breast cancer risk, their findings only partially agree. A 
pooled analysis, including data sets from the NHS I and 
NHS II cohorts with new data, found a 40% increased 
breast cancer risk (p=0.05) for premenopausal women 
with the highest (= upper level of the normal range) 
versus lowest quartile of PRL concentrations (Tworoger 
et al. 2007). However, in the EPIC studies a statistically 
non-significant association between PRL levels and 
breast cancer risk among premenopausal women was 
observed (Odds Ratio, OR=0.70; 95% Confidence 
Interval, 95%CI: 0.48–1.03 for invasive breast cancer 
and OR=1.30; 95%CI: 0.80–2.10 for in situ breast 
cancer) (Tikk et al. 2014a, 2015). With respect to 
postmenopausal women, a 30% increase in breast 
cancer risk (p=0.01) was demonstrated in the pooled 
analysis of the NHS cohorts (Tworoger et al. 2007).  
Table 3. Overview of Prospective Studies on Prolactin Concentrations and Breast Cancer Risk in Premenopausal and Post-
menopausal Women (Hankinson et al. 1999; Helzlsouer et al. 1994, Kabuto et al. 2000, Kwa et al. 1981, Manjer et al. 2003, 
Tikk et al. 2014a, 2015, Tworoger et al. 2004, 2006, 2007, 2013, 2015, Tworoger & Hankinson 2008, Wang et al. 1992) 
LEGEND: CI: Confidence Interval;    EPIC: European Prospective Investigation into Cancer;    ER: Estrogen Receptor;   
HRT: Hormone Replacement Therapy; HZ: Hazard Ratio;     N/A: Not Available;     NHS: Nurses’ Health Study;     NS: Not Significant; 
OR: Odds ratio; PR: Progesterone Receptor;     PRL: Prolactine; RR: Relative Risk;      
Italics: statistically significant data;     §: Including women with unknown menopausal status 
Table 3A. EPIC Database Study 
Study 
Number of Cases  
and Controls 
Premenopausal - Results Postmenopausal - Results 
Tikk
et al. 2015 
Premenopausal
86 cases/86 controls 
Postmenopausal
221 cases/221 controls 
OR=1.30; 95%CI:0.80–2.10 
(top versus bottom tertile) 
OR=1.38; 95%CI:1.00–1.91 (top versus bottom tertile) 
OR=1.20; 95%CI:0.82–1.76 (top versus bottom tertile for 
postmenopausal non-HRT-users)  
OR=1.77; 95%CI:0.98–3.21 (top versus bottom tertile for 
postmenopausal HRT-users) 
Tikk
et al. 2014a 
Premenopausal
512 cases/512 controls 
Postmenopausal
1,738 cases/1,738 
controls
OR=0.70; 95%CI:0.48–1.03 
(top versus bottom quartile) 
OR=0.70; 95%CI:0.44–1.09 
(ER+ cases) (top versus 
bottom quartile) 
OR=1.29; 95%CI:1.05–1.58 (top versus bottom quartile for 
all postmenopausal women) 
OR=1.11; 95%CI:0.83–1.49 (top versus bottom quartile for 
postmenopausal non-HRT-users)  
OR=1.45; 95%CI:1.08–1.95 (top versus bottom quartile for 
postmenopausal HRT-users)  
OR=1.29; 95%CI:1.02–1.63 (ER+ cases) (top versus bottom 
quartile for all postmenopausal women) 
OR=1.12; 95%CI:0.80–1.57 (ER+ cases) (top versus bottom 
quartile for postmenopausal non-HRT-users)  
OR=1.42; 95%CI:1.01–1.99 (ER+ cases) (top versus bottom 
quartile for postmenopausal HRT-users) 
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Table 3B. NHS Database Studies 
Study Number of Cases and Controls Premenopausal - Results Postmenopausal - Results 
Tworoger
et al. 2015 
Premenopausal
241 cases/241 controls 
Postmenopausal
119 cases/118 controls 
RR=0.99; 95%CI:0.71–1.37  
(top versus bottom quartile) 
RR=1.36; 95%CI:0.93–1.98  
(top versus bottom quartile) 
Tworoger
et al. 2013 
PRL collected <10 years before 
diagnosis
2,468 cases 
4,021 controls 
PRL collected >10 years before 
diagnosis
953 cases 
1,339 controls  
RR=1.05; 95%CI:0.82–1.33 (<10 
years) (top versus bottom quartile)
RR=0.98; 95%CI:0.73–1.32 (<10 
years, ER+ cases) (top versus 
bottom quartile) 
RR=1.03; 95%CI:0.68–1.56 (>10 
years) (top versus bottom quartile)
RR=0.81; 95%CI:0.51–1.30 (>10 
years, ER+ cases) (top versus 
bottom quartile) 
RR=1.37; 95%CI:1.11–1.69 (<10 years)  
(top versus bottom quartile) 
RR=1.52; 95%CI:1.19–1.93 (<10 years, ER+ 
cases) (top versus bottom quartile) 
RR=0.93; 95%CI:0.66–1.33 (>10 years) (top 
versus bottom quartile) 
RR=0.97; 95%CI:0.65–1.43 (>10 years, ER+ 
cases) (top versus bottom quartile) 
Tworoger & 
Hankinson
2008
Pooled analysis of approximately 
80% of the world’s prospective 
data
RR=1.3; 95%CI: 1.1–1.6 (top versus bottom quartile). Results were similar for 
premenopausal and postmenopausal women. High PRL levels were associated 
with a 60% increased risk of estrogen receptor positive tumors 
Tworoger
et al. 2007 
Premenopausal
New analysis 
377 cases 
786 controls 
Pooled analysis of new data with 
data sets from the NHS and NHS 
II cohorts 
492 cases 
1,001 controls 
Postmenopausal
Pooled analysis of new data with 
data sets from the NHS and NHS 
II cohorts 
915 cases 
1,410 controls 
RR=1.3; 95%CI:0.9–1.9  
(top versus bottom quartile) 
RR=1.4; 95%CI:1.0–1.9  
(top versus bottom quartile) 
RR=1.3; 95%CI:1.1–1.7  
(top versus bottom quartile) 
Tworoger
et al. 2006 
Premenopausal
316 cases/633 controls 
RR=1.5; 95%CI:1.0–2.5  
(top versus bottom quartile) 
Comparable RR=1.9;
95%CI:1.0-3.7 (ER+/PR+ tumors)
N/A
Tworoger
et al. 2004 
Postmenopausal
851 cases/1,275 controls 
N/A RR=1.34; 95%CI:1.02–1.76  
(top versus bottom quartile) 
RR=1.78; 95%CI:1.28–2.50  
(ER+/PR+ tumors) 
RR=0.76; 95%CI:0.43–1.32  
(ER-/PR- tumors) 
RR=1.94; 95%CI:0.99–3.78  
(ER+/PR- tumors) 
Hankinson
et al. 1999 
Postmenopausal
306 cases/448 controls 
N/A Multivariate RR=2.03; 95%CI: 1.24–3.31 
(top versus bottom quartile) 
This association differed by Estrogen/Progesterone 
(ER/PR) status, as the relative risk (RR) was found to be 
significant only for tumors with ER+/PR+ status 
(RR=1.78; 95%CI: 1.28–2.50) (Tworoger et al. 2007). 
Although the EPIC study equally found higher serum 
levels of PRL to be associated with a statistically signi-
ficant increase in breast cancer risk among postmeno-
pausal women (OR=1.29; 95%CI: 1.05–1.58), this 
increase in risk seemed to be confined to women who 
used hormone replacement therapy (HRT) at blood 
donation (OR=1.45; 95%CI: 1.08-1.95), whereas no 
statistically significant association was found for non-
users of HRT (OR=1.11; 95%CI: 0.83–1.49). They also 
found no evidence for heterogeneity of the PRL-breast 
cancer association by receptor status (Tikk et al. 2014a). 
Almost all prospective studies have studied the rela-
tionship between circulation PRL levels and invasive 
breast cancer (cancer that invades the surrounding 
tissues) risk. The association between PRL and in situ 
breast cancer (malignant cells but without invading the 
surrounding tissues, also called non-invasive cancer or 
pre-cancer) risk has received less attention. Neverthe-
less, a focus on in situ breast cancer offers the advan-
tage of exploring the associations with risk factors that 
are important early in the carcinogenic process (thus 
prior to development of invasive breast cancer) (Tikk et 
al. 2015). Three prospective studies have included 
subjects with in situ breast cancer (Manjer et al. 2003, 
Tikk et al. 2015, Tworoger et al. 2013). Of these only two 
provide estimates separately by in situ versus invasive 
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Table 3C. Other (Small) Prospective Studies 
Study Number of Cases and Controls Premenopausal - Results Postmenopausal - Results 
Manjer
et al. 2003 
Postmenopausal
173 cases/438 controls 
N/A Adjusted OR=1.34; 95%CI: 0.83–2.17 
(top versus bottom quartile) 
Kabuto
et al. 2000 
Premenopausal
46 cases/94 controls 
Postmenopausal
26 cases/56 controls 
OR=1.01; 95%CI: 0.02–47.4. 
For a log10 unit increase 
OR=6.45; 95%CI: 0.01–43.9.  
For a log10 unit increase 
Helzlsouer  
et al. 1994 
Premenopausal
21 cases/42 controls 
RR=1.1; 95%CI: 0.3–4.1  
(top versus bottom tertile) 
N/A
Wang
et al. 1992 
Premenopausal
71 cases/2,596 controls 
Postmenopausal
40 cases/1,180 controls 
RR=1.1; 95%CI: 0.5–2.2  
(top versus bottom quintile) 
RR=1.6; 95%CI: 0.6–4.7  
(top versus bottom quintile) 
Kwa  
et al. 1981 
Premenopausal
22 cases 
For each women who developed breast 
cancer, ten controls satisfying the matching 
requirements were available (in three cases 
only nine controls were available) 
Postmenopausal
8 cases 
For each women who developed breast 
cancer, ten controls satisfying the matching 
requirements were available (in three cases 
only nine controls were available) 
Not statistically significant 
(p=0.67)
8 cases 
Association between elevated plasma 
PRL levels and subsequent breast 
cancer is significant (p=0.04) and on 
average their values were at the 72nd 
percentile when compared to matched 
controls
breast cancer. In the Tworoger et al. (2013) study no 
increased risk has been found for in situ breast cancer 
among postmenopausal women with the highest versus 
lowest range of normal PRL levels (OR=1.16; 95%CI: 
0.77-1.74). On the other hand, Tikk et al. (2015) found a 
modest positive association between higher PRL levels 
and risk of in situ breast cancer among all women (pre-
and postmenopausal combined, OR=1.35; 95%CI: 1.04-
1.76). No statistically significant heterogeneity was 
found by menopausal status or HRT use at blood dona-
tion. One should be very cautious when interpreting 
prospective studies on the occurrence of in situ car-
cinoma, since this tumor is nearly always asymptomatic 
and mainly detected by microcalcifications on screening 
mammographies. The incidence of in situ carcinoma 
thus mainly depends on how actively the women have 
been screened. This information was generally lacking 
in the publications here cited. 
Some studies (Tikk et al. 2015, Tworoger et al. 
2013) found a differential association by time between 
blood collection and diagnosis, while others (Tikk et al. 
2014a) did not. Tikk et al. (2015) found that the 
relationship between PRL and in situ breast cancer was 
confined to tumors diagnosed within the first 4 years 
from blood donation. They observed that higher 
concentrations of PRL were significantly associated 
with in situ breast cancer less than 4 years since blood 
donation (OR=1.78; 95%CI: 1.12-2.84), but not with 
breast cancer diagnosed 4 or more years since blood 
donation (OR=1.09; 95%CI: 0.77-1.55). Similarly, 
Tworoger et al. (2013), in their 20-year prospective 
study, observed that PRL was only associated with 
breast cancer risk when assessed within 10 years before 
diagnosis, but no associations were observed for blood 
sampled 10 to 20 years before diagnosis. This was in 
contrast to what was observed for estradiol and testo-
sterone in the same population, in which levels predic-
ted risk for up to 16 to 20 years. 
Another way to address the question whether circu-
lating levels of PRL are important for the development 
of breast cancer, is to study patients with a tumor secre-
ting PRL (prolactinoma). Due to delays in diagnosis, 
these patients often have been exposed to increased PRL 
levels for months or even years and therefore are an 
interesting population for investigating the association 
between HPRL and breast cancer risk. Although there is 
a paucity of such data, two large cohort studies (Berin-
der et al. 2011, Dekkers et al. 2010) of patients treated 
for idiopathic HPRL or prolactinomas did not find any 
increased risk of breast cancer.  
A third interesting approach to explore the con-
tentious issue of possible carcinogenic effects of PRL is 
to look at patients with Parkinson’s disease (PD) who 
have low dopamine levels (Aziz et al. 2011, Lalonde & 
Myslobodsky 2003, Rugbjerg et al. 2012). On the basis 
of this observation, one would expect to find high PRL 
levels and a positive association between PD and breast 
cancer. However, results are inconsistent (Connolly & 
Lang 2014, Lalonde & Myslobodsky 2003).  
Taken together, we can conclude that results of 
human prospective studies are limited and equivocal 
(with risk ratios ranging from 0·70 to 1·9 for 
premenopausal women, and from 0·76 to 2·03 for 
postmenopausal women). Moreover, since the available 
data are correlational, the question of whether or not 
elevated PRL levels actually cause breast cancer 
remains unanswered. A recent review therefore stated 
that if PRL increases breast cancer risk, it is probably a 
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factor of (at most) modest magnitude. Well-known 
breast cancer risk factors probably are of greater rele-
vance than PRL when considering breast cancer risk and 
mortality (De Hert et al. 2016).  
Does a relationship exist between prolactin and 
established breast cancer risk factors?  
A number of studies have evaluated the association 
between PRL levels and several well-established breast 
cancer risk factors. Only the associations with nulli-
parity and hormone therapies (oral contraceptives, OC 
and HRT) have been firmly confirmed. It has been 
found that PRL levels among parous women are lower 
than those among nulliparous women (Hietala et al. 
2008, Tikk et al. 2014b). Although several studies 
(Ingram et al. 1990, Tikk et al. 2014b, Wang et al. 1988) 
have found a gradual decrease in PRL levels with 
increasing number of full-term pregnancy, in others 
(Eliassen et al. 2007, Musey et al. 1987, Nagata et al. 
2011) the parity associated decrease was only related to 
the first full-term pregnancy. Nevertheless, data have 
demonstrated that women that have given birth one or 
more times have 15-50% lower PRL levels than 
nulliparous women, with the majority of this decrease 
following the first full-term pregnancy (Eliassen et al. 
2007, Faupel-Badger et al. 2010a, Tworoger & 
Hankinson 2008). Mechanisms of the reduced PRL 
secretion after pregnancy are currently still unclear 
(Tikk et al. 2014b). Some studies have found that in 
parous women post-lactational PRL levels are lowered 
by longer breast-feeding duration of the first child, with 
no substantial effect on feeding subsequent children 
(Hietala et al. 2008). However, other studies (Eliassen et 
al. 2007, Tikk et al. 2014b) suggest that this association 
may be diminished with time, if present at all. Some 
reports have demonstrated a positive association 
between PRL levels and OC (Clevenger et al. 2003, 
Faupel-Badger et al. 2010a) or HRT use (Tikk et al. 
2014a, 2014b). Significantly higher levels of circulating 
PRL have been demonstrated among postmenopausal 
women who were currently using HRT, compared with 
women who did not use HRT. Whether these higher 
levels of PRL depend on the composition/type of the 
used HRT regimen is less clear (Tikk et al. 2014b).  
In conclusion, associations between higher circulating 
PRL levels and other breast cancer factor risk than nulli-
parity and hormone therapies (such as breast cancer-rela-
ted lifestyle risk factors) mostly have been negative for 
both pre-and postmenopausal women, even after adjus-
ting for parity (Clevenger et al. 2003, Eliassen et al. 
2007, Faupel-Badger et al. 2010a, Greendale et al. 2007, 
Tikk et al., 2014a, 2014b, Tworoger & Hankinson 2008). 
Is there evidence that, particularly PRL-
elevating, antipsychotic medication enhances 
breast cancer risk?  
The majority of the studies investigating the 
influence of antipsychotic medication on breast cancer 
risk have considered patients treated with FGA. These 
studies (Brugmans et al. 1973, Dalton et al. 2006, 
Kanhouwa et al. 1984, Kelly et al. 1999, Wagner & 
Mantel 1978) have not found an increased risk of breast 
cancer, an exception being the cohort study by Wang et 
al. (2002). These researchers conducted a retrospective 
cohort study in more than 100,000 women (including 
psychiatric patients as well as medical patients and 
patients from nursing homes) in which the relationship 
between FGA (and the SGA risperidone) and breast 
cancer risk was investigated. In this study, 52,819 wo-
men on dopamine antagonists were compared with 
55,289 women who were not on this medication. The 
authors found that, compared with non-users, women 
who used antipsychotic dopamine antagonists had a 
16% greater risk (adjusted Hazard Ratio=1.16, 95%CI: 
1.07–1.26) of developing breast cancer, with a dose-
response relationship between larger cumulative dosa-
ges and greater risk. However, as stated by the authors, 
the magnitude of the observed risk, although statistically 
significant, is small in absolute terms (1,239 cases of 
breast cancer in the user group versus 1,228 cases in the 
non-user group), and they estimated there is less than a 
14% chance that a dopamine antagonist user who 
develops breast cancer did so on the basis of her anti-
psychotic drug use. Moreover, although the power was 
limited, it is noteworthy that breast cancer risk was 
statistically significantly increased in those taking 
phenothiazines (e.g., chlorpromazine, perphenazine), 
but not butyrophenones (e.g., haloperidol), despite the 
fact that both FGA classes increase PRL by a similar 
amount (Holt & Peveler 2011, Madhusoodanan et al. 
2010). The authors therefore concluded that their fin-
dings “do not warrant changes in patients’ antipsychotic 
medication regimens” (Wang et al. 2002) (p. 1153). 
Despite these results, the study by Wang et al. has 
consistently been cited to demonstrate that antipsychotic 
medications can induce breast cancer, particularly in 
female patients with schizophrenia. Hippisley-Cox et al. 
(2007) tried to determine the risk of six common types 
of cancer in patients with schizophrenia or bipolar 
disorder (40,441 incident cases with up to five matched 
controls per case) and found a 52·2% increase in breast 
cancer risk in women with schizophrenia, compared 
with patients without mental health problems. However, 
only a small association with antipsychotic medication 
was found. The increase in breast cancer risk was not 
substantially different in subgroups with (FGA or SGA) 
and without antipsychotic medication use (adjusted 
OR=1.55 (95%CI: 1.08–2.23) for users and 1.43 
(95%CI: 0.68–3.01) for non-users, both compared with 
patients without mental health problems). In a large-
scale population-based cohort study of all residents in a 
Danish county, Dalton et al. (2006) found no increased 
risk for breast cancer among 25,264 FGA users 
(adjusted Incidence Rate Ratio=0.93; 95%CI: 0.74–
1.17), compared with residents of the same Danish 
county who did not receive such prescriptions. 
However, their inclusion criteria were very broad (for 
Marc De Hert, Davy Vancampfort, Brendon Stubbs, Tine Sabbe, Hans Wildiers & Johan Detraux: ANTIPSYCHOTIC TREATMENT, PROLACTIN, 
AND BREAST TUMORIGENESIS          Psychiatria Danubina, 2016; Vol. 28, No. 3, pp 243-254 
249
example 8,927 included patients had received merely 2-
4 prescriptions of antipsychotics and only 8·5% of 
female antipsychotic users had a diagnosis of 
schizophrenia), meaning that most of the included 
patients perhaps did not receive high and/or chronic 
doses of antipsychotics. In a systematic review of the 
literature on the potential pro-or anti-cancer activity of 
antipsychotics, Fond et al. (2012) included 93 studies 
(in vitro, animal and human studies) considering the 
effects of antipsychotic drugs (FGA + SGA) on cancer 
development and found that antipsychotics as a class 
cannot be considered as a risk factor for breast cancer 
in humans. 
Although SGA, as a group and compared to FGA, 
are associated with less PRL elevations, there are 
concerns that the SGA risperidone, amisulpride and 
paliperidone, which have been associated with a high 
prevalence of HPRL (Peuskens et al. 2014) (Table 1), 
may increase the risk of breast cancer. However, 
results indicate that SGA do not appear to increase the 
risk of breast cancer. Azoulay et al. (2011) conducted 
a retrospective cohort study (including 106,362 
patients prescribed at least one FGA or SGA) and 
matched all incident cases of breast cancer up to 10 
controls per case. They found that, compared to 
patients who only used FGA, exclusive users of SGA 
were not at an increased risk of breast cancer 
(RR=0.81, 95%CI: 0.63–1.05). These results remained 
consistent after considering specific SGA known to 
significantly increase PRL levels, such as risperidone 
(RR=0.86, 95%CI: 0.60–1.25). These findings were 
strengthened by the lack of any dose-response asso-
ciation, which considered both cumulative duration of 
use (patients were exposed for up to 23 years) and 
cumulative dose. Furthermore, no increased risk was 
observed in higher risk groups, such as in post-
menopausal women.  
Thus, on the basis of the available data, it can be 
concluded that, until now, no causal link between 
(chronic) administration of antipsychotics and breast 
tumorigenesis in humans has been shown.  
A different, but strongly related issue is whether 
antipsychotics can also increase the risk of relapse after 
prior treatment for early breast cancer, or whether it 
promotes tumor growth in patients with metastatic 
breast cancer. Despite the absence of controlled studies, 
the lack of a clear association between antipsychotics 
and breast tumorigenesis and reports that antipsychotic 
medications display potential anticancer activity (see 
further) is reassuring, and suggests that PRL does not 
influence breast cancer biology importantly. A recent 
review concluded that, as until today evidence is 
unconvincing and insufficient, even breast cancer 
patients may not be deprived of potentially effective 
antipsychotic medications for serious psychiatric 
indications and revised medication guidelines are 
needed to avoid the existing undertreatment of serious 
psychiatric problems among these patients (Froes 
Brandao et al. 2016).  
DISCUSSION 
Besides the fact that the existing evidence concer-
ning a possible relationship between PRL and breast 
tumorigensis is limited, equivocal and correlational, 
thus precluding any claims regarding causality, some 
other important considerations have to be made.  
Firstly, studies examining the relationship between 
elevated PRL levels and breast cancer risk primarily 
have used immunoassays to measure PRL concen-
trations. This method captures multiple PRL isoforms 
and thus may not reflect the activity of the specific 
bioactive monomeric PRL hormone (with a molecular 
mass of 23 kiloDalton, kDA) which is supposed to be 
most relevant to breast carcinogenesis (Froes Brandao et 
al. 2016). Although the 23kDA PRL is the most 
common form of circulating PRL, forms with a higher 
(or lower, see further) molecular mass, such as the “big” 
(50-kDA) PRL and the “big-big” (150-kDA) PRL or 
macroprolactin, are also present, which both are 
essentially biologically inactive. Moreover, glycosylated 
23kDA PRL has a lower biologic activity due to 
reduced binding to its receptors than the non-
glycosylated 23kDA PRL form. In most normal 
subjects, the 23kDA monomeric PRL acounts for ~65-
85% of the total circulating PRL (of which only ~40-
65% is non-glycosylated), the 50kDA “big” PRL 
accounts for ~10-20%, while the 150kDA “big-big” 
PRL or macroprolactin contributes <10%. However in 
case of HPRL, the level of any or all of these forms can 
be raised and their relative proportions can vary 
considerably. This is important to know as the presence 
of macroprolactin, for example, may lead to falsely high 
PRL levels as measured by many assays, particularly in 
patients where this form of PRL accounts for significant 
proportions of the total circulating PRL (Fahie-Wilson 
& Smith 2013).  
Secondly, studies investigating the relationship 
between PRL levels and breast cancer risk have also 
predominantly focused on circulating PRL levels. 
However, PRL functions not only in an endocrine 
manner, where it is secreted by the pituitary and acts on 
distant tissues such as the mammary gland, but also in 
an autocrine/paracrine [i.e., locally produced PRL from 
mammary (tumor) cells that acts directly on the cell 
itself (autocrine) or neighboring cells (paracrine)] 
fashion (Ben-Jonathan et al. 2002, Clevenger et al. 
2003, Muthuswamy 2012). Amplification (or over-
expression) of the autocrine/paracrine loop within the 
breast tissue has, based on several observations, been 
suggested to be one of the mechanisms underlying the 
participation of local PRL in tumorigenesis (Fernandez 
et al. 2010). Animal and in vitro data have shown that 
PRL stimulates breast cancer cell proliferation, survival 
and migration via binding to the cell-surface PRL 
receptor (Ben-Jonathan et al. 2002, Clevenger et al. 
2003, Moorman et al. 2013, Oakes et al. 2008, Perks et 
al. 2004, Sethi et al. 2012, Wen et al. 2014). The exact 
mechanism whereby this occurs, however, remains 
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poorly understood (Tikk et al. 2015). Although the 
extrapituitary production of PRL may not cause 
detectable systemic changes in serum PRL (Chen 2015), 
it is nevertheless immediately available to local breast 
cancer cells and could be biologically very significant in 
terms of oncogenesis (Chen 2015, Harvey 2012, Sethi et 
al. 2012). Extra-pituitary PRL expression escapes nega-
tive control by dopamine. Although dopamine agonists, 
such as bromocriptine, are very efficient at reducing 
pituitary PRL levels in hyperprolactinemic patients, 
they are ineffective for targeting autocrine/paracrine 
PRL, meaning that this source of the hormone cannot be 
controlled by PRL-lowering drugs that act on the 
pituitary (Harvey 2012). Some observations (Chen 
2015, Nitze et al. 2013) suggest that an autocrine/ 
paracrine effect by PRL is unlikely to be a general 
mechanism promoting breast cancer cell growth and 
that the role of PRL as an autocrine/paracrine growth 
factor should be reevaluated (Chen 2015).  
Thirdly, after the proposal that the PRL/PRLR 
pathway could play an etiological role in breast cancer, 
the race began to search for an effective PRLR blocker 
(Chen 2015). Efforts to develop a PRL receptor 
blocking agent (Damiano & Wasserman 2013) have 
failed so far, and all such drug candidates to date in 
monotherapy have proven to be ineffective (Chen 2015, 
Froes Brandao et al. 2016). Moreover, it also has been 
shown that PRLR expression is associated with better 
clinical outcome in patients with breast cancer and 
therefore may be more likely to play a protective and 
suppressive role in breast cancer rather than a promoting 
role (Hachim et al. 2016).  
Several lines of evidence suggest that PRL can have 
‘protective’ attributes. It has been shown that PRL can 
act as invasion/metastasis suppressor hormone in breast 
cancer (Nouhi et al. 2006). The 16kDA PRL isoform, 
which is a PRL fragment of the full-length 23 kDA PRL 
hormone, has been shown to have anti-angiogenic 
effects in vivo (Faupel-Badger et al. 2010b). Angio-
genesis or blood vessel formation is indispensable for 
breast cancer development and progression and PRL 
can act as a stimulatory (the unmodified, full-length 23 
kDA PRL hormone) or inhibitory (the proteolytic PRL 
fragments ranging from 14 to 18kDA, also known as 
vasoinhibins) factor on growth, dilatation and remo-
deling of blood vessels. In its (anti)-angiogenic function 
PRL can act both as a circulating hormone and in an 
autocrine/paracrine fashion (Andres & Djonov 2010). In 
breast cancer, the role of PRL could depend on the 
production of vasoinhibins, which can be generated 
from systemic PRL or from PRL produced and secreted 
by human breast cancer cells. Reduced levels of 
vasoinhibins (due to low levels of protease activity) 
create a more favourable angiogenic condition for tumor 
progression (Clapp et al. 2008). This supports the 
complex role of PRL and puts forward the concept that 
PRL may possess a dual role in breast carcinogenesis, 
acting as a growth and survival factor (pro-oncogenic) 
as well as suppressor hormone. 
Considering the possible association between 
antipsychotic medication, PRL, and breast cancer risk, 
further well conducted research is needed to assess the 
extent, if any, to which antipsychotics contribute to the 
increase of breast cancer risk in people using 
antipsychotics, over and above other breast cancer risk 
factors. Moreover, several reports describe mecha-
nisms of cancer protection with antipsychotic medica-
tion. Recently, studies have revealed that anti-
psychotics, such as phenothiazines, pimozide or 
penfluridol, have antiproliferative activity and promote 
apoptosis in different types of cancer, including breast 
cancer (Amson et al. 2013, Gil-Ad et al. 2004, Ke et 
al. 2014, Lu et al. 2015, Min et al. 2014, Ranjan et al. 
2016, Sachlos et al. 2012, Wiklund et al. 2010, Wu et 
al. 2014, Wuonola et al. 1998, Yeh et al. 2012, Zhelev 
et al. 2004). Thioridazine, belonging to the pheno-
thiazine drug group, targets breast cancer and achieves 
a synergistic effect with other antiproliferative drugs. 
For example, it has been shown that co-delivery of 
thioridazine and doxorubicin, a highly potent and 
widely used chemotherapeutic agent for the treatment 
of various types of cancers including breast cancer, 
may provide a promising strategy for breast cancer 
treatment by targeting both cancer cells and cancer 
stem cells. Cancer stem cells express a high level of 
dopamine receptors, and the selective antiproliferative 
effect of thioridazine against the cancer stem cells 
might occur via the dopamine receptor antagonism (Ke 
et al. 2014). Ranjan et al. (2016) demonstrated the 
anti-metastatic effects of the FGA penfluridol in breast 
cancer models. Their results indicated that penfluridol 
effectively reduces the growth of primary triple-
negative breast cancer tumors and especially 
metastatic growth in the brain. Wu et al. (2014) 
showed that penfluridol is not only cytotoxic to cancer 
cells in vitro but can also inhibit tumor growth in vivo. 
Dysregulation of cholesterol homeostasis by 
penfluridol may be involved in its anti-tumor 
mechanisms. Finally, it has been shown in vitro that 
the (PRL-elevating) phenothiazines (e.g., thioridazine 
and chlorpromazine) may be promising anti-hormone 
therapy sensitizing compounds for enhancing the 
effect of tamoxifen, one of the cornerstone anti-
hormonal treatments for breast cancer patients, in 
tamoxifen-resistant human breast cancer cells (Huang 
et al. 2011, Yde et al. 2009). A recently conducted 
study demonstrated a conceivable resolution of tamo-
xifen-induced side effects when using the PRL-
elevating SGA compound risperidone, without 
interfering the efficacy of tamoxifen against breast 
cancer in both in vitro and in vivo models (Yeh et al. 
2014). If antipsychotics are used in breast cancer 
patients receiving anticancer therapy, drug-drug 
interactions always need to be checked. However, for 
tamoxifen, antipsychotics generally give much less 
interactions than antidepressant drugs which often 
interfere with cytochrome P450 2D6 (CYP2D6) just 
like tamoxifen (Desmarais & Looper 2009). 
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Several experts (Peveler et al. 2008, Rahman et al. 
2014), as well as the product labelling of most (the 
exceptions being aripiprazole and clozapine) anti-
psychotics advise one has to be careful to use PRL-
elevating antipsychotics in breast cancer patients or 
patients with a past history or family history of breast 
cancer. This advise is of course something different than 
the scope of this review focusing on breast cancer risk. 
Although certain antipsychotics (i.c., the PRL-elevating 
antipsychotic olanzapine) have been used effectively 
without safety concerns in the management of chemo-
therapy-induced nausea and vomiting in patients with 
breast cancer (Lau et al. 2016, Navari 2014, 2016), until 
now, no controlled studies about the effect of 
antipsychotics on the prognosis of women with breast 
cancer have been conducted. Although it must be clear 
that antipsychotics should not be withhold for breast 
cancer prevention reasons to patients in need of this 
sometimes life-saving medication, even if classical 
breast cancer risk factors are present, clinicians must 
weigh, as with any case, the potential benefits and risks 
of using these medications in patients with breast 
cancer. In fact, it may be more reasonable to use these 
drugs in breast cancer patients when there are strong 
clinical reasons to prescribe such medications, for 
example in patients where schizophrenia is life-
threatening and/or very debilitating or the risk of 
seriously exacerbating the disease by avoiding anti-
psychotic treatment may outweigh the possible risk of 
elevated PRL levels. It is advisable that the oncologist 
and clinician be involved together with the patient to 
arrive at an informed decision.  
CONCLUSIONS 
After years of scientific research, the true role of 
PRL in breast cancer etiology remains elusive (Chen 
2015). Results of prospective studies considering the 
effect of pituitary PRL on breast cancer risk are 
inconsistent and only partially agree. In studies 
evaluating the relationship between pituitary PRL levels 
and breast cancer risk factors, only the associations with 
nulliparity and hormone therapies (OC and HRT) have 
been confirmed. Until today, no causal link between 
(chronic) administration of antipsychotics and breast 
tumorigenesis in humans has been shown. Finally, anti-
psychotic-induced HPRL is not mentioned by the 
National Cancer Institute (2016) as an established 
factor increasing a woman’s risk of breast cancer 
(Rahman et al. 2014). In the recently published up-
dates of the World Federation of Societies of Bio-
logical Psychiatry (WFSBP) guidelines, breast cancer 
is not recognized as a potential adverse outcome of 
antipsychotic-induced HPRL (Hasan et al. 2013). This 
recommendation, together with results of studies 
concerning antipsychotics and breast cancer risk in 
women with schizophrenia, should provide some 
reassurance to both clinicians and their patients on the 
(long-term) safety of these agents.  
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